- Al-Kuraishy, H. M., Al-Gareeb, A. I., Waheed, H. J., & Al-Maiahy, T. J. Differential effect of metformin and/or glyburide on apelin serum levels in patients with type 2 diabetes mellitus: Concepts and clinical practice. Journal of Advanced Pharmaceutical Technology & Research 2018; 9(3): 80–86.
- Olguner Eker, Ö. Özsoy, S., Eker, B., & Doğan, H. (2017). Metabolic Effects of Antidepressant Treatment. Noro Psikiyatri Arsivi 2017; 54(1): 49–56.
- Ng D. S. Diabetic dyslipidemia: from evolving pathophysiological insight to emerging therapeutic targets. Canadian Journal of Diabetes 2013; 37(5): 319–326.
- ElBatsh M. M. Antidepressant-like effect of simvastatin in diabetic rats. Canadian Journal of Physiology and Pharmacology 2015; 93(8): 649–656.
- El-Marasy, S. A. Abdallah, H. M., El-Shenawy, S. M., El-Khatib, A. S., El-Shabrawy, O. A., & Kenawy, S. A. . Anti-depressant effect of hesperidin in diabetic rats. Canadian Journal of Physiology and Pharmacology 2014; 92(11): 945–952.
- Rachdi, C., Damak, R., Fekih Romdhane, F., Ouertani, H., & Cheour, M. Impact of sertraline on weight, waist circumference and glycemic control: A prospective clinical trial on depressive diabetic type 2 patients. Primary Care Diabetes 2019; 13(1): 57–62.
- Clemens, K. K., McArthur, E., Dixon, S. N., Fleet, J. L., Hramiak, I., & Garg, A. X. The hypoglycemic risk of glyburide (glibenclamide) compared with modified-release gliclazide. Canadian Journal of Diabetes 2015; 39 Suppl 4: 32–40.
- Barnard, K., Peveler, R. C., & Holt, R. I. (2013). Antidepressant medication as a risk factor for type 2 diabetes and impaired glucose regulation: systematic review. Diabetes Care 2013; 36(10): 3337–3345.
- Roopan, S., & Larsen, E. R. (2017). Use of antidepressants in patients with depression and comorbid diabetes mellitus: a systematic review. Acta Neuropsychiatrica 2017; 29(3); 127–139.
- Lustman, P. J., Clouse, R. E., Nix, B. D., Freedland, K. E., Rubin, E. H., McGill, J. B., Williams, M. M., Gelenberg, A. J., Ciechanowski, P. S., & Hirsch, I. B. Sertraline for prevention of depression recurrence in diabetes mellitus: a randomized, double-blind, placebo-controlled trial. Archives of General Psychiatry 2006; 63(5): 521–529.
- Ahmadi, A., Khalili, M., Margedari, S. h., & Nahri-Niknafs, B. The Effects of Solvent Polarity on Hypoglycemic and Hypolipidemic Activities of Securigera Securidaca (L.) Seeds. Drug Research 2016; 66(3): 130–135.
- Latha, R. C., & Daisy, P. Insulin-secretagogue, antihyperlipidemic and other protective effects of gallic acid isolated from Terminalia bellerica Roxb. In streptozotocin-induced diabetic rats. Chemico-biological Interactions 2011; 189(1-2): 112–118.
- Ahmadi, A., Khalili, M., Seyedhoseyni, S., Roudsari, E. M., & Nahri-Niknafs, B. Synthesis, antidiabetic and hypolipidemic activities of new diethylamine and triethoxysilyl derivatives of tolbutamide on rats. Medicinal Chemistry 2012; 8(5): 964–969.
- Pollak, P. T., Mukherjee, S. D., & Fraser, A. D. Sertraline-induced hypoglycemia. The Annals of Pharmacotherapy 2001; 35(11):1371–1374.
- Takhar, J., & Williamson, P. Hypoglycemia associated with high doses of sertraline and sulphonylurea compound in a noninsulin-dependent diabetes mellitus patient. The Canadian journal of Clinical Pharmacology 1999; 6(1): 12–14.
- Shuster, D. L., Risler, L. J., Prasad, B., Calamia, J. C., Voellinger, J. L., Kelly, E. J., Unadkat, J. D., Hebert, M. F., Shen, D. D., Thummel, K. E., & Mao, Q. Identification of CYP3A7 for glyburide metabolism in human fetal livers. Biochemical Pharmacology 2014; 92(4): 690–700.
- Preskorn, S. H., Greenblatt, D. J., Flockhart, D., Luo, Y., Perloff, E. S., Harmatz, J. S., Baker, B., Klick-Davis, A., Desta, Z., & Burt, T. Comparison of duloxetine, escitalopram, and sertraline effects on cytochrome P450 2D6 function in healthy volunteers. Journal of Clinical Psychopharmacology 2007; 27(1), 28–34.
- Juan, D., Molitch, M. E., Johnson, M. K., Carlson, R. F., & Antal, E. J. (1990). Unaltered drug metabolizing enzyme systems in type II diabetes mellitus before and during glyburide therapy. Journal of Clinical Pharmacology 1990; 30(10): 943–947.
- Chi, T. C., Ho, Y. J., Chen, W. P., Chi, T. L., Lee, S. S., Cheng, J. T., & Su, M. J. Serotonin enhances beta-endorphin secretion to lower plasma glucose in streptozotocin-induced diabetic rats. Life Sciences 2007; 80(20): 1832–1838.
- Bymaster, F. P., Zhang, W., Carter, P. A., Shaw, J., Chernet, E., Phebus, L., Wong, D. T., & Perry, K. W. Fluoxetine, but not other selective serotonin uptake inhibitors, increases norepinephrine and dopamine extracellular levels in prefrontal cortex. Psychopharmacology 2002; 160(4): 353–361.
- Katzung B TA, Masters S. Katzumg & Trevor’s Pharmacology Examination and Board Review. Katzumg & Trevor’s Pharmacology Examination and Board Review. McGraw Hill Professional 2008; 250-3.
- Sumara, G., Sumara, O., Kim, J. K., & Karsenty, G.. Gut-derived serotonin is a multifunctional determinant to fasting adaptation. Cell Metabolism 2012; 16(5): 588–600.
- Garland, M. R., Hallahan, B., McNamara, M., Carney, P. A., Grimes, H., Hibbeln, J. R., Harkin, A., & Conroy, R. M. Lipids and essential fatty acids in patients presenting with self-harm. The British Journal of Psychiatry: The Journal of Mental Science 2007; 190: 112–117.
- Steegmans, P. H., Fekkes, D., Hoes, A. W., Bak, A. A., van der Does, E., & Grobbee, D. E. Low serum cholesterol concentration and serotonin metabolism in men. British Medical Journal 1996; 312(7025): 221.
- Rozzini, R., Bertozzi, B., Barbisoni, P., & Trabucchi, M. Low serum cholesterol and serotonin metabolism. Risk of depression is higher in elderly patients with lowest serum cholesterol values. British Medical Journal 1996; 312(7041): 1298–1299.
- Ban, Y., Watanabe, T., Miyazaki, A., Nakano, Y., Tobe, T., Idei, T., Iguchi, T., Ban, Y., & Katagiri, T. Impact of increased plasma serotonin levels and carotid atherosclerosis on vascular dementia. Atherosclerosis 2007; 195(1): 153–159.
- Lara, N., Baker, G. B., Archer, S. L., & Le Mellédo, J. M. Increased cholesterol levels during paroxetine administration in healthy men. The Journal of clinical Psychiatry 2003; 64(12): 1455–1459.
- Buydens-Branchey, L., Branchey, M., Hudson, J., & Fergeson, P. Low HDL cholesterol, aggression and altered central serotonergic activity. Psychiatry Research 2000; 93(2): 93–102.
- Kortz, W. J., Schirmer, B. D., Nashold, J. R., Jones, R. S., & Meyers, W. C. Effects of serotonin on canine bile formation. Surgery 1985; 98(5): 907–913.
- Chan, A. K., & von der Weid, P. Y. 5-HT decreases contractile and electrical activities in lymphatic vessels of the guinea-pig mesentery: role of 5-HT 7-receptors. British Journal of Pharmacology 2013; 139(2): 243–254.
|